Dixon Hubard Feinour & Brown’s Teva Pharmaceuticals TEVA Stock Holding History

Dixon Hubard Feinour & Brown’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-4,603	Closed	-$302K	–	181
2015 Q4	$302K	Hold	4,603	–	–	0.1%	134
2015 Q3	$260K	Buy	4,603 +546	+13%	+$35.4K	0.1%	132
2015 Q2	$240K	Sell	4,057 -1,850	-31%	-$114K	0.07%	154
2015 Q1	$368K	Buy	5,907 +167	+3%	+$9.71K	0.11%	132
2014 Q4	$330K	Buy	+5,740	New	+$320K	0.1%	140

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dixon Hubard Feinour & Brown's TEVA Position: Q1 2016 in Review

Dixon Hubard Feinour & Brown sold out of Teva Pharmaceuticals (TEVA) in Q1 2016, closing a stake of 4,603 shares — an estimated $302K sold.

Dixon Hubard Feinour & Brown first reported a position in TEVA in Q4 2014 and held it in 5 quarters. The position peaked at $368K in Q1 2015. 836 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

Dixon Hubard Feinour & Brown reported no remaining Teva Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Dixon Hubard Feinour & Brown sold 4,603 Teva Pharmaceuticals shares in Q1 2016, an estimated $302K.
Dixon Hubard Feinour & Brown first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 5 quarters.
Dixon Hubard Feinour & Brown's Teva Pharmaceuticals position peaked at $368K in Q1 2015.
836 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on Dixon Hubard Feinour & Brown's 13F filing for Q1 2016, filed 9 May 2016.